Revenue from operations at Rs 1,963 Cr, up 17.7% YoY EBITDA margins at 18.4% with EBITDA up 23.2% YoY PAT at 156Cr, up 30.3% YoY Domestic business sales at 888 Cr, up 12.0% YoY International business sales at 1,075 Cr, up 23.0% YoY Emcure Pharmaceuticals
On Thursday, Emcure Pharmaceuticals announced a significant step forward in HIV treatment access through a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a subsidiary of Gilead Sciences based in California. This collaboration will allow Emcure to manufacture and supply generic versions of lenacapavir,
